A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioloalveolar carcinoma (BAC) or no smoking history
Michael Smylie(Inserm), Helen J. Ross(Rush University), Afshin Dowlati(University Hospitals of Cleveland), Frances A. Shepherd(University Health Network), Tal Zaks(Moderna Therapeutics (United States)), Jennifer Garst(Dartmouth–Hitchcock Medical Center), H. Hassani(Dartmouth–Hitchcock Medical Center), G. R. Blumenschein, M. S. Berger(Duke University), James R. Rigas(Dartmouth–Hitchcock Medical Center)
Cited by 32
Related Papers
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
|New England Journal of Medicine|2016|1.3k